The human T-cell leukemia virus, type I (HTLV-I), has been implicated as the cause of an aggressive and often fatal neoplasm of T4+ lymphocytes termed adult T-cell leukemia (ATL) (1-3). However, unlike many other acutely transforming animal retroviruses, HTLV-I does not appear to contain a viral oncogene related to a cellular gene (4, 5) . Furthermore, insertional mutagenesis by the virus appears unlikely since the site of proviral integration varies markedly in different tumors (6) . A striking feature of HTLV-I-infected leukemia T-cell lines is the constitutive high level expression of IL-2 receptors (IL-2R) (7) (8) (9) and, rarely, the simultaneous production of IL-2 (10, 11) . Speculation has focused on the possibility that the inappropriate expression of these cellular genes, which play an important role in regulating normal T-cell growth, may be involved in the development of ATL (11) . However, the mechanism by which HTLV-I alters IL-2R, and occasionally IL-2, gene expression is unresolved. Like some DNA-transforming viruses (12, 13) , HTLV-I contains a transactivator (tat-I, x-lor, p40X) gene (14) whose 40,000 Mr protein product is able to stimulate transcription of other viral genes by direct or indirect interaction with a trans-activation responsive region located within the viral long terminal repeat (LTR) (15) (16) (17) . These trans-acting transcriptional properties of tat-I raise the possibility that this protein might also be able to alter the expression of certain cellular genes including IL-2R and IL-2. In this regard, Inoue et al. (18) have reported that the p40" (tat-I) protein of HTLV-I induces the transient expression of the endogenous IL-2R and IL-2 genes in Jurkat and HSB-2 T cells. We have studied effects of tat-I by constructing expression plasmids encoding functional tat-I protein or, alternatively, a nontrans-activating protein (Atat-I) also derived from the pX region of HTLV-I. Effects of these viral gene products on the promoter segments of the IL-2R and IL-2 genes linked to the chloramphenicol acetyltransferase (CAT; EC 2.3.1.28) reporter gene were evaluated in transient cotransfection assays.
MATERIALS AND METHODS
Cells and Reagents. Jurkat, MT-1 (a gift from I. Miyoshi, Kochi Medical School) (19) , YT cells (a gift from J. Yodoi, Kyoto University, Kyoto, Japan) (20) , and MLA-144 T cells (21) were cultured in RPMI-1640 medium (GIBCO) supplemented with 10% fetal calf serum, 2.0 mM L-glutamine, and antibiotics. In some experiments, phytohemagglutinin (PHA, 1 ,ug/ml, Burroughs Wellcome, Research Triangle Park, NC), OKT3 monoclonal antibody (100 ng/ml, Ortho Diagnostics), phorbol 12-myristate 13-acetate (PMA, 50 ng/ml, Sigma), and/or cyclosporin A (CSA, 1 ,tg/ml, Sandoz Pharmaceutical) were added.
Construction of Expression Vectors and Promoter-CAT Plasmids. The plasmids used in these experiments are schematically depicted in Fig. 1 . All constructions were made following general procedures (22) . The tat-I (spFMTLTR/82-2C) and Atat-I (spFMTLTR/62-6) plasmids were prepared with cDNAs isolated from a XgtlO cDNA library prepared by using poly(A)-enriched mRNA from the HTLV-I-infected C91/PL T-cell line. The tat-I cDNA encodes the 40,000 Mr tat-I protein as well as a 27,000 Mr protein derived from the X-III reading frame of HTLV-I (data not shown). The Atat-I cDNA is derived from a mRNA utilizing an alternative splicing pattern within the pX region and does not encode the 40,000 Mr tat-I protein but does produce a 21,000 Mr protein derived from the X-III reading frame. Only the tat-I cDNA trans-activates the HTLV-I LTR (data not shown). These cDNAs were excised with EcoRI and inserted into the unique (28) . RSV-CAT (29) , GALV-CAT (30), and visna-CAT (a gift of C. Rosen, Dana-Farber Cancer Institute) contain, respectively, the LTRs of Rous sarcoma virus (RSV), gibbon ape leukemia virus (GALV), and visna virus promoting expression of the CAT gene.
Cotransfection Analyses of Promoter Activity. DNA was transfected into the cell lines by the DEAE-dextran method (30) . Five micrograms of the tat-expressing or control plasmid and 5 ,ug of the appropriate promoter-CAT construct were cotransfected into 107 cells. PHA, OKT3, and/or PMA were added after 24 hr of culture. Cells were collected for assay after an additional 20 hr of incubation. CAT assays and thin-layer chromatography were performed as described (31) . (Table 2 ). As in Jurkat T cells, the IL-2R-CAT plasmid was activated in GALV-transformed MLA-144 T cells by the tat-I protein and mitogenic stimuli (PHA and PMA). In contrast, although tat-I augmented IL-2R-CAT expression in HTLV-I-infected MT-1 cells (which do not produce detectable levels of tat-I protein) (19) , mitogenic stimulation of these cells was largely without effect. A different pattern of IL-2R-CAT stimulation was found in the "natural killer-like" YT cell line. Although the addition of PHA and PMA produced marked stimulation of IL-2R-CAT activity in these cells, tat-I was completely ineffective.
RESULTS

Comparison of Activation Requirements for Endogenous
Effect of tat-I on pIL-2-CAT Expression. In contrast to the stimulatory effects on IL-2R-CAT expression in Jurkat T cells, the tat-I protein alone was found to have little or no stimulatory effect on IL-2-CAT activity in the absence of other stimuli ( Fig. 3 ; Table 1 , line 4). However, when one of a number of different activation signals (PHA, PMA, or OKT3, each of which alone was ineffective) was added in concert with tat-I, marked activation of IL-2-CAT expression was produced (Fig. 3) . Specifically, the tat-I protein, but not the Atat-I protein, synergized with PHA, PMA, and OKT3 to produce, respectively, a 58-fold, 20-fold, and 3-fold increase in IL-2-CAT activity (Table 1, lines 3 and 4) . Although the stimulation with tat-I and OKT3 is modest, it is similar to that observed with the combination of OKT3 and PMA.
The tat-I Protein Partially Circumvents CSA Inhibition of IL-2-CAT Expression. CSA is a potent immunosuppressive agent that regulates IL-2 activity in Jurkat cells by blocking mitogen-activated transcription of the IL-2 gene (37, 38) . Similarly, CSA completely blocked the activation of IL-2-CAT expression induced by PHA and PMA in the cotransfection assays (Fig. 4) . In contrast, the inhibitory effects of CSA were partially abrogated by the presence of the tat-I protein (Fig. 4) . For example, in cells stimulated with tat-I in the presence of CSA, 27% of the CAT activity remained after PHA induction, 79% remained after PMA induction, and 47% remained after addition of both PHA and PMA (Fig. 4 and  data not shown) .
Effects of the tat-I Protein on Other Cellular and Viral Promoters. In contrast to the IL-2-CAT and IL-2R-CAT plasmids, expression of other transfected cellular and viral promoters was unaffected by the tat-I protein, either when added alone or in the presence of PHA and/or PMA. As shown in Table 3 , expression of the myc promoter, the RSV LTR, the /8-actin promoter linked to the SV40 enhancer, the GALV LTR, or the visna virus LTR was not significantly altered by the tat-I protein alone in Jurkat T cells ( Table 3 ). The myc, RSV, and actin promoters also were not markedly activated in these cells by PHA and PMA, either in the presence or absence of the tat-I protein. In contrast, both the GALV and visna virus LTRs were activated by the mitogenic stimuli. However, the tat-I protein did not produce a further increase in their expression.
DISCUSSION
In these studies, we have examined the potential stimulatory effects of the trans-activator gene product (tat-I) of HTLV-I on the cellular regulatory sequences governing IL-2 and IL-2R gene expression. We have demonstrated that the tat-I protein in Jurkat T cells is able to activate the IL-2R promoter in the absence of any other mitogenic signals. These effects do not appear to simply reflect generalized nonspecific activation, as the tat-I protein fails to alter the expression of other cellular and viral promoters (Table 3 ). In addition, analyses of various lymphoid cell lines revealed that mitogen and tat-I induction of the IL-2R promoter were not always correlated (Table 2) .
In contrast to its capacity to activate the IL-2R promoter, the tat-I protein alone produces little or no stimulation of the IL-2 promoter in Jurkat T cells. The tat-I protein, however, is able to synergize with other mitogenic stimuli (PHA, PMA, OKT3), which alone are ineffective, to markedly activate the IL-2 promoter. These costimulatory effects of tat-I and mitogen on IL-2-CAT expression also appear to be specific since combinations of these agents do not alter expression of several other cellular or viral promoters. Thus, the tat-I protein is able to provide one of the two signals required for IL-2 gene expression and, interestingly, can substitute in this response either for PHA or PMA. The similarity of the ultimate site of action of PHA and PMA predicted by this result is supported by the studies of Fujita et al. (39) , who have concluded that the same region of the IL-2 promoter is involved in both PMA and concanavalin A induction.
We have also observed that tat-I-mediated costimulation of the IL-2 promoter partially circumvents the inhibitory effects of CSA. Though the mechanism of CSA inhibition of IL-2 (46) . Such tat-Iinduced autocrine proliferation might facilitate the occurrence of the second-stage events required for the completion of the T-cell transformation process and lead to the later outgrowth of a clonal population of growth factor-independent leukemia T cells. As tat-I activity is often low or undetectable in these IL-2-independent cells, its presence may not be required for maintenance of the transformed state. In support of an autocrine stage in leukemogenesis, Arima et al. (47) have identified primary ATL tumor cells whose proliferation, at least in part, involves the simultaneous display of IL-2R and the production of IL-2. It seems likely that the tat-I protein plays an important role in the induction of HTLV-I-associated malignancy not only by amplifying viral replication but also by deregulating the expression of the cellular genes that normally control T-cell growth, including IL-2 and IL-2R.
Note. Since submission of this paper, Maruyama et al. (48) 
